5‐Hydroxytryptamine Medications for the Treatment of Obesity
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The central 5‐hydroxytryptamine (5‐HT; serotonin) system represents a fundamental component of the brain's control of energy homeostasis. Medications targeting the 5‐HT pathway have been at the forefront of obesity treatment for the past 15 years. Pharmacological agents targeting 5‐HT receptors (5‐HTR), in combination with genetic models of 5‐HTR manipulation, have uncovered a role for specific 5‐HTR s in energy balance and reveal the 5‐HT2C R as the principal 5‐HTR mediating this homeostatic process. Capitalising on this neurophysiological machinery, 5‐HT2C R agonists improve obesity and glycaemic control in patient populations. The underlying therapeutic mechanism has been probed using model systems and appears to be achieved primarily through 5‐HT2C R modulation of the brain melanocortin circuit via activation of pro‐opiomelanocortin neurones signalling at melanocortin4 receptors. Thus, 5‐HT2C R agonists offer a means to improve obesity and type 2 diabetes, which are conditions that now represent global challenges to human health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503
Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356
Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene
Farooqi, I. S., Keogh, J. M., Yeo, G. S. H., Lank, E. J., Cheetham, T., & O'Rahilly, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022050 · Cited by 1,778
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
Neurobiology of food intake in health and disease
Morton, G. J., Meek, T. H., & Schwartz, M. W. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3745 · Cited by 748
The human raphe nuclei and the serotonergic system
Hornung, J.-P. (2003) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2003.10.002 · Cited by 742
Rossi, J., Balthasar, N., Olson, D., Scott, M., Berglund, E., Lee, C. E., Choi, M. J., Lauzon, D., Lowell, B. B., & Elmquist, J. K. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.01.010 · Cited by 672
Cited by
Leptin and the maintenance of elevated body weight
Pan, W. W., & Myers, M. G. (2018) · Nature reviews. Neuroscience · doi:10.1038/nrn.2017.168 · Cited by 344
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Nucleus of the Solitary Tract Serotonin 5-HT2C Receptors Modulate Food Intake
D'Agostino, G., Lyons, D., Cristiano, C., Lettieri, M., Olarte-Sanchez, C., Burke, L. K., Greenwald-Yarnell, M., Cansell, C., Doslikova, B., Georgescu, T., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.017 · Cited by 149
Self-citationvan Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146
Augmented capacity for peripheral serotonin release in human obesity
Young, R. L., Lumsden, A. L., Martin, A. M., Schober, G., Pezos, N., Thazhath, S. S., Isaacs, N. J., Cvijanovic, N., Sun, E. W. L., Wu, T., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0047-8 · Cited by 87
Apryatin, S. A., Shipelin, V. A., Trusov, N. V., Mzhelskaya, K. V., Evstratova, V. S., Kirbaeva, N. V., Soto, J. S., Fesenko, Z. S., Gainetdinov, R. R., & Gmoshinski, I. V. (2019) · Physiological Reports · doi:10.14814/phy2.13987 · Cited by 28
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
“Even though pharmacotherapies targeting the 5-HT pathway have been considered for obesity treatment for the past several years, new research on pharmacologic agents targeting 5-HT receptors (5-HTR), in combination with genetic models of 5-HTR manipulation, has uncovered a role for specific 5-HTRs in energy balance.(14…”
BackgroundPapathanasiou, A. E., Nolen-Doerr, E., Farr, O. M., & Mantzoros, C. S. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0847 · Cited by 20
Metadata
- Authors
- Burke, L. K., & Heisler, L. K.
- Venue
- Journal of Neuroendocrinology
- Publisher
- Wiley
- Published
- 2015-05-26
- Volume
- 27
- Issue
- 6
- Pages
- 389-398
- ISSN
- 0953-8194 (ISSN-L)
- 1365-2826
- OpenAlex
- W1505713219
- Cited by
- 80
- References
- 16
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.